Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    New Hope for Drug Discovery in African Sleeping Sickness

    By Global Biodefense StaffOctober 27, 2014
    Michael Pollastri Conducting Neglected Disease Drug Discovery
    Credit: Brooks Canaday/Northeastern University
    Share
    Facebook LinkedIn Reddit Email

    In early drug discovery, you need a starting point, says Northeastern University associate professor of chemistry and chemical biology Michael Pollastri.

    In a new research paper recently published the journal PLOS Neglected Tropical Diseases, Pollastri and his colleagues present hundreds of such starting points for potentially treating African sleeping sickness, a deadly disease that claims thousands of lives annually.

    Pollastri, who runs Northeastern’s Laboratory for Neglected Disease Drug Discovery, and collaborators at the Spanish National Research Council for Scientific Research worked with global healthcare company GlaxoSmithKline to screen and test more than 42,000 chemical compounds against the parasites that cause African sleeping sickness. In their paper, they report identifying nearly 800 compounds that represent good options for early drug discovery.

    “Having this many good starting points for discovery of new drugs for sleeping sickness is a big deal and could ultimately lead to a cure,” Pollastri said.

    Pollastri also highlighted another exciting component to this project. Previously, he created a data- sharing portal where scientists and researchers can access and contribute to each other’s work on neglected tropical diseases. This new research on African sleeping sickness will be the first data to be deposited on the portal, which was supported by a crowd­funding campaign.

    “This is a venue where other people, particularly medical chemists from around the world, can contribute to the project in one way or the other,” Pollastri said.

    African sleeping sickness is one of the World Health Organization’s 17 neglected tropical diseases. It is found only in sub-Sahara Africa and infects between 10,000 and 30,000 people annually. Tsetse flies transmit the disease and symptoms come in two stages. In the first stage an infected person experiences symptoms such as fever, headaches, joint pains, and itching. In the second stage, parasites enter the person’s central ner­vous system and that leads to sleep cycle disruption, coma and, if untreated, death.

    “It is a nasty, nasty disease,” said Pollastri, adding that it hasn’t been widely researched and that even the current drug treatments are lengthy, toxic, and often fatal themselves.

    Pollastri and his co-collaborators worked with Dr. Miguel Navarro at the Spanish National Research Council in Granada, Spain, and with GlaxoSmithKline’s OpenLab initiative to run the screenings, which focused on inhibitors that block the process of phosphoryl transfer mediated by enzymes called kinases. This process is a key step in cellular signaling, and kinase inhibitors have been historically pursued for potential treatment of some cancers and inflammatory disorders, he explained.

    The next step will involve continued testing on these promising 800 compounds and determining which ones can be tweaked in order to have the right potency, properties, and lack of toxicity to treat the disease, he said. At that point, they may be able to advance a compound toward clin­ical trials for sleeping sickness.

    Read the study at PLOS Neglected Tropical Diseases: Identification and Characterization of Hundreds of Potent and Selective Inhibitors of Trypanosoma brucei Growth from a Kinase-Targeted Library Screening Campaign.

    Human African Trypanosomiasis Neglected Tropical Diseases Tsetse Flies
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleShorter TB Treatment Not A Successful Alternative
    Next Article Battelle Wins CBRNE Contract from CENTCOM

    Related Stories

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023

    Call for Experts: Smallpox Medical Countermeasures

    October 28, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.